A RANDOMIZED, PLACEBO-CONTROLLED, CROSS-OVER TRIAL INVESTIGATING NABILONE AS A TREATMENT FOR AGITATION IN PATIENTS WITH MODERATE-TO-SEVERE ALZHEIMER'S DISEASE: BLINDED, INTERIM SAFETY RESULTS